Quince Therapeutics Inc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| QNCX | ATHE | VYGR | QNTM | GANX | PRQR | |
|---|---|---|---|---|---|---|
| Market cap | — | 46.58M | 115.23M | 14.21M | 48.44M | 198.98M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -2.9 | -1.5 | -0.3 | -1.6 | -3.0 |
| Price/book | — | 1.5 | 0.7 | 2.1 | 4.3 | 2.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | — | −30.29% | −55.69% | −74.27% | −41.58% | −36.20% |
| Today | +8.07% | −1.21% | +2.19% | 0.00% | −3.48% | +2.92% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All QNCX news ›San Francisco's $10B Dupe Retailer Quince Crosses the Atlantic Into the UK
None of this runs through physical stores. Quince has no brick-and-mortar locations and relies entirely on ecommerce, though it has experimented with pop-ups, including a recent furniture pop-up in Los Angeles. The UK offer mirrors the…
Quince Therapeutics (IRLA) 10K Form and Latest SEC Filings 2026 | MarketBeat
An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update. Browse Quince Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K,…
Quince Therapeutics
is a clinical-stage biotechnology company focused on developing treatments for rare diseases with significant unmet medical needs. The company’s primary program is EryDex, an investigational therapy designed to deliver dexamethasone…
More from 1 other outlet
PERCEPTIVE ADVISORS LLC Acquires 912,853 Shares of Quince Therapeutics Inc (QNCX)
PERCEPTIVE ADVISORS LLC Acquires 912,853 Shares of Quince Therap GuruFocus PERCEPTIVE ADVISORS LLC Acquires 912,853 Shares of Quince Therapeutics Inc (QNCX) A Strategic Entry into a Clinical-Stage Biotech On 2026-10-06, PERCEPTIVE ADVISORS…
Quince Therapeutics: Tananbaum reports 6.0% stake
Preferred shares underpin a passive stake above 5% in Quince Therapeutics (QNCX). Stock Titan - [SCHEDULE 13G] Quince Therapeutics, Inc. Passive Investment Disclosure (>5%) Quince Therapeutics: Tananbaum reports 6.0% stake The 6.0%…
Quince Therapeutics approves 4 conditional board picks
Quince Therapeutics, Inc. (QNCX) disclosed conditional changes to its board: June Bray, David Lamond and Christopher Senner tendered resignations that would take effect two business days after the October 6, 2026 special meeting concludes,…
Quince Therapeutics holders approve over 20% share issuance
QTREX Quantum Announces Clean Capital Structure The charter amendment raises authorized common stock to 275,000,000 shares, and both approved plans include annual reserve-increase provisions through 2036. Of 1,017,063 shares outstanding on…
Quince Therapeutics, Inc. Announces Management and Committee Changes, Effective October 8, 2026
Quince Therapeutics, Inc. announced that Leone Patterson, age 63, Ms. Patterson served as Executive Vice President, Chief Business Officer and Chief Financial Officer of Zymeworks, Inc. from September... announced that Leone Patterson, age…
Raymond James Initiates Quince Therapeutics at Outperform With $72 Price Target
Quince Therapeutics has an average rating of buy and mean price target of $74.75, according to analysts polled by FactSet. ... Biotechnology & Medical Research Raymond James Initiates Quince Therapeutics at Outperform With $72 Price Target…
Cantor Fitzgerald Initiates Quince Therapeutics at Overweight With $4 Price Target
... Biotechnology & Medical Research Cantor Fitzgerald Initiates Quince Therapeutics at Overweight With $4 Price Target Published on 06/23/2026 at 07:13 am EDT
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- tradingview.com12
- marketscreener.com8
- stocktitan.net5
- marketbeat.com2
- defenseworld.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 32 articles, not a forecast.